The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
Open accessAbstract
Resistance to alkylating agents via direct DNA repair by O 6-methylguanine methyltransferase (MGMT) remains a significant barrier to the successful treatment of patients with malignant glioma. The relative expression of MGMT in the tumor may determine response to alkylating agents, and epigenetic silencing of the MGMT gene by promoter methylation plays an important role in regulating MGMT expression in gliomas. MGMT promoter methylation is correlated with improved progression-free and overall survival in patients treated with alkylating agents. Strategies to overcome MGMT-mediated chemoresistance are being actively investigated. These include treatment with nontoxic pseudosubstrate inhibitors of MGMT, such as O 6-benzylguanine, or RNA interference-mediated gene silencing of MGMT. However, systemic application of MGMT inhibitors is limited by an increase in hematologic toxicity. Another strategy is to deplete MGMT activity in tumor tissue using a dose-dense temozolomide schedule. These alternative schedules are well tolerated; however, it remains unclear whether they are more effective than the standard dosing regimen or whether they effectively deplete MGMT activity in tumor tissue. Of note, not all patients with glioblastoma having MGMT promoter methylation respond to alkylating agents, and even those who respond will inevitably experience relapse. Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Self-citationInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Self-citationA gene hypermethylation profile of human cancer.
Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. (2001) · PubMed · Cited by 2,032
Self-citationEsteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Self-citationYung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (2000) · PubMed · Cited by 891
Self-citationStupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Self-citationNewlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationPegg, A. E. (1990) · PubMed · Cited by 730
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Repair of O6-alkylguanine by alkyltransferases
Pegg, A. E. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00017-x · Cited by 576
Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase
Pegg, A. E., Dolan, M. E., & Moschel, R. C. (1995) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60879-x · Cited by 506
MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer
Shen, L., Kondo, Y., Rosner, G. L., Xiao, L., Hernandez, N. S., Vilaythong, J., Houlihan, P. S., Krouse, R. S., Prasad, A. R., Einspahr, J. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji275 · Cited by 498
Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2007) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 495
Self-citationPhase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488
Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 452
Clinical Relevance of MGMT in the Treatment of Cancer
Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 428
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Mismatch repair and DNA damage signalling
Stojic, L., Brun, R., & Jiricny, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.006 · Cited by 396
Tolcher, A. W., Gerson, S. L., Denis, L., Geyer, C., Hammond, L. A., Patnaik, A., Goetz, A. D., Schwartz, G., Edwards, T., Reyderman, L., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600827 · Cited by 368
Godard, S., Getz, G. A., Delorenzi, M., Farmer, P. J., Kobayashi, H., Desbaillets, I., Nozaki, M., Diserens, A., Hamou, M., Dietrich, P., et al. (2003) · PubMed · Cited by 319
Self-citationHermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Self-citationJaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Ochs, K., & Kaina, B. (2000) · PubMed · Cited by 291
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288
Phase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Athanassiou, H., Synodinou, M., Maragoudakis, E., Paraskevaidis, M., Verigos, C., Misailidou, D., Antonadou, D., Saris, G., Beroukas, K., & Karageorgis, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.331 · Cited by 272
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Self-citationPaz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L., García-Lopez, J. L., Piquer, J., Safont, M.-J., Balaña, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0392 · Cited by 261
Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C., Williams, L., Foster, T., Sepkowitz, K. A., & Chapman, P. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.060 · Cited by 257
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244
Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., Schamus, S., & Sobol, R. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0715 · Cited by 242
Preusser, M., Charles Janzer, R., Felsberg, J., Reifenberger, G., Hamou, M., Diserens, A., Stupp, R., Gorlia, T., Marosi, C., Heinzl, H., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00153.x · Cited by 242
Self-citationTanwar, M. K., Gilbert, M. R., & Holland, E. C. (2002) · PubMed · Cited by 241
Self-citationDumenco, L. L., Allay, E., Norton, K., & Gerson, S. L. (1993) · Science · doi:10.1126/science.8421782 · Cited by 236
Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V, Franceschi, E., Biscuola, M., Blatt, V, Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 228
Mechanisms of tolerance to DNA damaging therapeutic drugs
Karran, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.12.1931 · Cited by 226
Bernd, K., Fritz, G., Mitra, S., & Coquerelle, T. (1991) · Carcinogenesis · doi:10.1093/carcin/12.10.1857 · Cited by 220
Qian, X. C., & Brent, T. P. (1997) · PubMed · Cited by 214
Watts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., & Futscher, B. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5612 · Cited by 214
Chinot, O. L., Barrié, M., Fuentes, S., Eudes, N., Lancelot, S., Metellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P.-M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4807 · Cited by 212
Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., et al. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070169 · Cited by 197
Self-citationQuinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.084 · Cited by 189
Unmasking a killer: DNA O6-methylguanine and the cytotoxicity of methylating agents
Bignami, M., O'Driscoll, M., Aquilina, G., & Karran, P. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00016-8 · Cited by 185
Brell, M., Tortosa, A., Verger, E., Gil, J. M., Viñolas, N., Villá, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0230 · Cited by 182
Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S., & Gerson, S. L. (1999) · PubMed · Cited by 162
Self-citationOne week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Wick, W., Steinbach, J. P., Küker, W., DICHGANS, J., BAMBERG, M., & Weller, M. (2004) · Neurology · doi:10.1212/01.wnl.0000127617.89363.84 · Cited by 155
Self-citationBeyond the genetic lesions: gene inactivation by promoter hypermethylation in human cancer
Esteller, M., Baylin, S. B., & Herman, J. G. (2000) · Revista de Oncología · doi:10.1007/bf02979467 · Cited by 139
Self-citationSpiro, T. P., Gerson, S. L., Liu, L., Majka, S. M., Haaga, J. R., Hoppel, C. L., Ingalls, S. T., Pluda, J. M., & Willson, J. K. V. (1999) · PubMed · Cited by 126
Self-citationFolate‐maytansinoids: Target‐selective drugs of low molecular weight
Ladino, C. A., Chari, R. V. J., Bourret, L. A., Kedersha, N., & Goldmacher, V. S. (1997) · International Journal of Cancer · Cited by 120
Grombacher, T., MITRA, S. P., & Kaina, B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2329 · Cited by 119
Friedman, H. S., Pluda, J. M., Quinn, J. A., Ewesuedo, R. B., Long, L., Friedman, A. H., Cokgor, I., Colvin, O. M., Haglund, M. M., Ashley, D. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3522 · Cited by 116
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Crinière, E., Kaloshi, G., Laigle–Donadey, F., Lejeune, J., Auger, N., Benouaich‐Amiel, A., Everhard, S., Mokhtari, K., Polivka, M., Delattre, J., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9320-0 · Cited by 93
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
Maxwell, J. A., Johnson, S. P., Quinn, J. A., McLendon, R. E., Ali‐Osman, F., Friedman, A. H., Herndon, J. E., Bierau, K., Bigley, J. W., Bigner, D. D., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0106 · Cited by 88
Redmond, S. M. S., Joncourt, F., Buser, K., Ziemiecki, A., Altermatt, H. J., Fey, M. F., Margison, G. P., & Cerny, T. (1991) · PubMed · Cited by 86
Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications
Hill, C. E., HUNTER, S. B., & Brat, D. J. (2003) · Advances in Anatomic Pathology · doi:10.1097/00125480-200307000-00004 · Cited by 84
Silber, J. R., Blank, A., Bobola, M. S., Mueller, B. A., Kolstoe, D. D., Ojemann, G. A., & Berger, M. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6941 · Cited by 79
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide
Ganière, V., Christen, G., Bally, F., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0514 · Cited by 46
Zaidi, N. H., Liu, L., & Gerson, S. L. (1996) · PubMed · Cited by 43
Self-citationMethylation-Specific Polymerase Chain Reaction
Galm, O., & Herman, J. G. (2005) · Humana Press eBooks · doi:10.1385/1-59259-916-8:279 · Cited by 43
Self-citationTemozolomide: A Milestone In the Pharmacotherapy of Brain Tumors
Weller, M., Steinbach, J. P., & Wick, W. (2005) · Future Oncology · doi:10.2217/14796694.1.6.747 · Cited by 39
Self-citationNeyns, B., Chaskis, C., Joosens, E. J., Menten, J. J., D'Hondt, L. A., Branle, F., Sadones, J., & Michotte, A. (2008) · Cancer Investigation · doi:10.1080/07357900701708393 · Cited by 39
Chen, Z. P., Yarosh, D. B., Garcia, Y., Tampieri, D. I., Mohr, G., Malapetsa, A., Langleben, A., & Panasci, L. (1999) · PubMed · Cited by 38
Is protracted low-dose temozolomide feasible in glioma patients?
Tosoni, A., Cavallo, G., Ermani, M., Scopece, L., Franceschi, E., Ghimenton, C., Gardiman, M. P., Pasetto, L. M., Blatt, V., & Brandes, A. A. (2006) · Neurology · doi:10.1212/01.wnl.0000196465.83423.ec · Cited by 37
Cited by
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Metadata
- Authors
- Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-01
- Volume
- 26
- Issue
- 25
- Pages
- 4189-4199
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131981377
- Cited by
- 812
- References
- 71
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.